PCa CTCs are reported to reflect those mutations present in the primary tumor e.g., TMPRSS2-ERG fusions, androgen receptor mutations, and PTEN deletion which, together with PSA, AMACR and androgen receptors, can predict the response to treatment [176,177]. The gene discussed is PTEN; the disease is neoplasm.